FSH vs Kisspeptin-54

Binds FSH receptors on Sertoli cells in testes to support sperm maturation and inhibin B production. In women, binds granulosa cell FSH receptors to drive follicular growth and estradiol production.

FSH (follicle-stimulating hormone) is an endogenous heterodimeric glycoprotein hormone produced and secreted by pituitary gonadotrophs, composed of a non-covalently associated common alpha subunit shared with LH, TSH, and hCG, and a unique FSH-specific beta subunit that confers receptor specificity; it is the primary regulator of gametogenesis in both sexes, acting on ovarian granulosa cells and testicular Sertoli cells to drive reproductive development. FSH activates its cognate receptor (FSHR) through cAMP-mediated signaling to stimulate follicular maturation and estradiol synthesis in the ovary via aromatase upregulation, and to support spermatogenesis in the testis by promoting Sertoli cell function and germ cell proliferation; FSH levels rise dramatically at menopause as negative feedback from ovarian estrogen declines. A Cochrane systematic review and meta-analysis established that recombinant FSH preparations are clinically equivalent to urinary-derived gonadotropins for ovarian stimulation in assisted reproductive technology cycles, providing the evidence base underlying current ART practice; this review supports the use of recombinant FSH as the standard of care for controlled ovarian hyperstimulation. FDA-approved recombinant FSH preparations — follitropin alfa (Gonal-f) and follitropin beta (Follistim) — require a prescription and are indicated for ovulation induction and ART in women and for hypogonadotropic hypogonadism in men; endogenous FSH is not administered as a therapeutic agent, and research-grade recombinant FSH is used as a cell culture tool and reproductive biology research compound.

Full-length kisspeptin (54 amino acids); binds KISS1R on GnRH neurons with higher receptor occupancy and longer duration than KP-10; induces more sustained GnRH/LH pulses

Kisspeptin-54 (Kp-54) is the primary full-length endogenous form of the KISS1-derived peptide family, a hypothalamic neuropeptide that acts as the central regulator of GnRH pulsatility and reproductive hormone signaling. As a KISS1R agonist, kisspeptin-54 directly stimulates GnRH neurons, initiating LH and FSH release from the pituitary and driving downstream gonadal steroidogenesis in both males and females. Published research documents kisspeptin-54 regulation of the reproductive axis across the menstrual cycle and its emerging potential as a treatment for sexual dysfunction, with studies suggesting effects on reproductive hormone output and libido-related pathways. Kisspeptin-54 is an investigational compound; it is not approved by the FDA for any clinical indication and its applications in sexual health and fertility remain under active investigation. Kisspeptin-54 vs kisspeptin-10: length and activity distinctions Kisspeptin-54 (Kp-54) is the full-length 54-amino-acid endogenous KISS1-derived peptide, while kisspeptin-10 (Kp-10) is the C-terminal decapeptide fragment responsible for KISS1R (GPR54) binding activity. Both isoforms activate the same receptor, but Kp-54 has a longer plasma half-life and sustained GnRH-stimulating activity relative to the shorter fragment, making it the preferred form for clinical research contexts where prolonged hormonal response is required. In research settings, Kp-10's lower cost and simpler synthesis has led to its wider use in mechanistic studies, while Kp-54 is preferred in clinical trials involving ovulation induction. Kisspeptin-54 in IVF: A published phase 2 clinical trial (Abbara et al., NEJM 2020) demonstrated that kisspeptin-54 could serve as an ovulation trigger in IVF — replacing the conventional hCG trigger in women at high risk of ovarian hyperstimulation syndrome (OHSS). The kisspeptin-54 trigger produced lower OHSS rates compared to hCG while maintaining acceptable oocyte yields, establishing it as a clinically relevant alternative trigger agent for high-risk patients. This application positions kisspeptin-54 within fertility medicine as a potential hCG substitute rather than just a mechanistic research tool. It remains investigational outside of trial contexts and is not currently approved by the FDA or EMA for ovulation induction.